--- title: "National Framework Agreement for Adalimumab Injection 1 April 2023" ocid: "ocds-h6vhtk-037c6c" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-037c6c" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-037c6c.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-037c6c.json" source: "Find A Tender Service" current_stage: "Award" buyer: "NHS ENGLAND" published: "2023-03-24" --- # National Framework Agreement for Adalimumab Injection 1 April 2023 Buyer: NHS ENGLAND Current stage: Award OCID: ocds-h6vhtk-037c6c [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-037c6c) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-037c6c.json) ## Summary The National Framework Agreement for Adalimumab Injection commencing on 1 April 2023 is a completed procurement project by NHS England. The agreement covers multiple regions including South of England, Midlands and East, London, and North of England. It includes options for extensions up to 24 months, with various contract periods for each lot. The procurement method used was an open procedure, with award criteria based on price. The main procurement category is goods within the pharmaceutical products industry. This tender offers significant business opportunities for pharmaceutical companies looking to supply Adalimumab Injection to NHS regions in England. The procurement process involves active supplier involvement, as evidenced by multiple awards made to companies like Amgen Ltd, Sandoz Ltd, Biogen, Abbvie Ltd, Fresenius Kabi Limited, and Celltrion Healthcare United Kingdom Limited. Businesses interested in this opportunity should consider registering their interest on the NHS eTendering portal and complying with the submission requirements before the bid validity period ends on 26th February 2023. ## Notice Project Title: NHS National Framework Agreement for the supply of Adalimumab Injection commencing 1 April 2023 Offer reference number: CM/PHR/22/5660 CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months ### Lot Information CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Lot 4 - CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to the North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Lot 3 - CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to the London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Lot 1 - CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/008624-2023 | | Notice type | Tender Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Large, SME | | All stages | Tender, Award | ## Dates | Field | Value | | --- | --- | | Publication date | 24 Mar 2023 | | Submission deadline | 28 Nov 2022 | | Future notice date | Not specified | | Award date | 14 Mar 2023 | | Contract period | 31 Mar 2023 - 31 Aug 2024 | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £478,880,000 | | Lots value | £478,880,000 | | Awards value | Not specified | | Contracts value | £1 | ## Status | Field | Value | | --- | --- | | Tender status | Complete | | Lots status | Cancelled | | Awards status | Active | | Contracts status | Active | ## Buyer | Field | Value | | --- | --- | | Main buyer | NHS ENGLAND | | Locality | LEEDS | | Post town | Leeds | | Postcode | LS2 7UE | | Country | England | | ITL 1 | TLE Yorkshire and The Humber | | ITL 2 | TLE4 West Yorkshire | | ITL 3 | TLE42 Leeds | | Local authority | Leeds | | Electoral ward | Little London & Woodhouse | | Westminster constituency | Leeds Central and Headingley | | Delivery location | Not specified | ## Supplier | Field | Value | | --- | --- | | Number of suppliers | 6 | | Supplier names | ABBVIE; AMGEN; BIOGEN; CELLTRION HEALTHCARE UNITED KINGDOM; FRESENIUS KABI; SANDOZ | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33600000 - Pharmaceutical products ## Release History - 24 Mar 2023 at 11:45 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/008624-2023 - 26 Oct 2022 at 14:03 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/030223-2022 ## Notice URLs - http://health.atamis.co.uk - https://health-family.force.com/s/Welcome - https://supplierregistration.cabinetoffice.gov.uk - https://www.england.nhs.uk/ - https://www.gov.uk/courts-tribunals - https://www.judiciary.uk/courts-and-tribunals/high-court/ ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-037c6c. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-037c6c.json.